Recent Updates
Recently added Catalysts

PT2385

Phase 1

Healthy | Small molecule | Other |Merck & Company, Inc.|Last Updated: Dec 10, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment16
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02553356PT2385-102 Food Effect Study of PT2385 in Healthy VolunteersPHASE1 COMPLETED 16Sep 1, 2015Dec 1, 2015Dec 10, 20151 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Effect of food on the pharmacokinetics of a single dose of PT2385 Tablets administered to normal healthy adult subjects (Cmax).
6 days

Peak Plasma Concentration (Cmax) will be assessed in both the fasting and non-fasting conditions and compared.

Secondary Endpoints
Safety and tolerability of PT2385 Tablets in normal healthy adult subjects by reviewing the incidence of treatment-emergent adverse events.
30 days
Pharmacodynamic (PD) effects of treatment with PT2385 Tablets (plasma levels).
6 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
FastedEXPERIMENTALPT2385 taken after fasting.
Non-FastingEXPERIMENTALPT2385 taken after eating a high calorie meal.
Interventions
NameTypeDescription
PT2385DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Female between 18 and 45 years of age; * If of childbearing potential, willing to practice methods of birth control; * If of childbearing potential, must be non-pregnant and non-lactating and have a negative serum pregnancy test result prior to enrollment into the trial; * Has...

Countries:United States
Unlock Eligibility Criteria